Last updated: February 11, 2023
Sponsor: Institute of Liver and Biliary Sciences, India
Overall Status: Active - Recruiting
Phase
N/A
Condition
Diabetes Prevention
Metabolic Disorders
Liver Disease
Treatment
N/AClinical Study ID
NCT05696808
ILBS-NAFLD
Ages 18-60 All Genders
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
- Patients recently diagnosed (<3 months)diagnosed on the basis of ultrasound and /orliver transient eleastography (controlled attenuation parameter; CAP >250)
- Having components of metabolic syndrome like Hyperglycemia, central obesity,hypertension, hypertriglyceridemia, and low HDL cholesterol levels).
Exclusion
Exclusion Criteria:
- Pregnant & lactating women
- Age <18 and >55 years
- Individuals who had been hospitalised with complications of Diabetes mellitus, ChronicKidney disease, Hypertension in the previous 6 months
- Those with intake of antibiotics within last month
- Seriously ill and bed ridden patients
- Patients with viral hepatitis
- Patients with significant alcohol consumption (regular consumption of > 10g per dayfor females and > 20g/d in males),
- Patients having chronic inflammatory bowel disease or any chronic and autoimmunediseases will be excluded
- Patients with NAFLD with associated hypertriglyceridemia requiring administration ofstatins.
Study Design
Total Participants: 60
Study Start date:
January 16, 2023
Estimated Completion Date:
January 13, 2024
Study Description
Connect with a study center
Institute of Liver and Biliary Sciences
New Delhi, Delhi 110070
IndiaActive - Recruiting

Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.